{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:21Z","timestamp":1788416001286,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Trible\u2010seronegative myasthenia gravis (tSNMG) is defined as myasthenia gravis (MG) without detectable or low affinity antibodies to acetylcholine receptor (AChR), muscle\u2010specific kinase (MuSK) andlipoprotein related protein 4(LRP-4). This article reports a case of a 39-year-old married female patient with thymoma-associated seronegative myasthenia gravis (tSNMG), which was accompanied by multiple positive autoantibodies and a benign mediastinal lesion. The primary manifestation was generalized muscle weakness, involving the limbs, bulbar muscles, and respiratory muscles. After admission, the patient showed poor responses to treatments including pyridostigmine bromide, human immunoglobulin, glucocorticoids, and tacrolimus. Ultimately, following therapy with efgartigimod followed by rituximab, significant symptomatic improvement was observed. By analyzing the diagnosis and treatment process of this case alongside relevant literature, this report explores the therapeutic value of efgartigimod followed by rituximab for tSNMG, key points for individualized regimen adjustments, and the challenges in diagnosis and treatment, thereby providing a reference for the clinical management of such refractory cases.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1848629","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:51Z","timestamp":1788412911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of sequential efgartigimod and rituximab treatment for tSNMG"],"prefix":"10.3389","volume":"17","author":[{"given":"Hua","family":"Xie","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College of Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Ting","family":"Pan","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]},{"name":"Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2013a new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-374279-7.15006-4","article-title":"Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis","volume":"31","author":"Martinez-Harms","year":"2024","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2277","article-title":"Seronegative myasthenia gravis\u2014a vanishing disorder","volume":"73","author":"Kaminski","year":"2016","journal-title":"JAMA Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664131","article-title":"Differential expression profiles of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple seronegative myasthenia gravis","volume":"16","author":"Hao","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-2963.2025.06.004","article-title":"\u827e\u52a0\u83ab\u5fb7\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u4ee5\u547c\u5438\u56f0\u96be\u8d77\u75c5\u7684MuSK\u6297\u4f53\u9633\u6027\u91cd\u75c7\u808c\u65e0\u529b1\u4f8b\u62a5\u9053","volume":"32","author":"\u90d1\u827a\u660e","year":"2025","journal-title":"\u4e2d\u56fd\u795e\u7ecf\u514d\u75ab\u5b66\u548c\u795e\u7ecf\u75c5\u5b66\u6742\u5fd7"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70418","article-title":"Rituximab in new-onset generalized myasthenia gravis: long-term follow-up of the RINOMAX clinical trial","volume":"32","author":"Wu","year":"2025","journal-title":"Eur J Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1439899","article-title":"Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251388019","article-title":"Open-label study of efgartigimod in seronegative myasthenia gravis","volume":"18","author":"Khateb","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08096-9","article-title":"Efgartigimod improves non-AChR generalized myasthenia gravis: a real world experience","volume":"46","author":"Antozzi","year":"2025","journal-title":"Neurol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health\u2010related quality of life in generalized myasthenia gravis: results from a randomized, double\u2010blind, placebo\u2010controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113694-20250120-00041","article-title":"\u4e2d\u56fd\u91cd\u75c7\u808c\u65e0\u529b\u8bca\u65ad\u548c\u6cbb\u7597\u6307\u5357(2025\u7248)","volume":"58","year":"2025","journal-title":"\u4e2d\u534e\u795e\u7ecf\u79d1\u6742\u5fd7"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16306","article-title":"Overcoming therapeutic challenges: successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod","volume":"31","author":"Sorrenti","year":"2024","journal-title":"Eur J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2025-004655","article-title":"Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)","volume":"25","author":"Jacob","year":"2025","journal-title":"Pract Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:53Z","timestamp":1788412913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2026.1848629"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848629","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1848629"}}